The following represents disclosure information provided by authors of this abstract. The Gastrointestinal Cancers Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Phase II trial of irinotecan, S-1, and bevacizumab (IRIS/Bev) combination chemotherapy as second line for advanced colorectal cancer (NCCSG04).
Yasumasa Takii
No relevant relationships to disclose
Kouichi Hurukawa
No relevant relationships to disclose
Satoshi Maruyama
No relevant relationships to disclose
Toshiyuki Yamazaki
No relevant relationships to disclose
Jun Nishimura
No relevant relationships to disclose
Mikako Kawahara
No relevant relationships to disclose
Takemi Tomiyama
No relevant relationships to disclose
Kohei Akazawa
No relevant relationships to disclose
Katsuyoshi Hatakeyama
No relevant relationships to disclose